Filing Details

Accession Number:
0001225208-16-036060
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-07-05 12:56:21
Reporting Period:
2016-07-05
Filing Date:
2016-07-05
Accepted Time:
2016-07-05 12:56:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
310158 Merck & Co. Inc. MRK Pharmaceutical Preparations (2834) 221918501
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1168014 M Mirian Weir Graddick Merck &Amp; Co., Inc.
2000 Galloping Hill Road
Kenilworth NJ 07033
Exe V-P, Hr No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-07-05 9,000 $57.92 123,151 No 4 S Direct
Common Stock Disposition 2016-07-05 36,000 $58.00 87,151 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.8600 to $58.0000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.0000 to $58.0400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
  4. Holdings include shares acquired in dividend reinvestment transactions.